Current opinion in gastroenterology
Cure8 research brief
Why This Matters
Nutrition support choices (enteral vs parenteral) can affect remission, healing, and complications in IBD, post-surgical recovery, and critical illness. Understanding current evidence helps patients and clinicians make individualized feeding decisions.
Who Should Pay Attention
Adult patients with IBD or GI cancer, post-surgery patients, clinicians managing nutrition support, and researchers studying nutrition, critical care, or the gut microbiome.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This review summarizes recent evidence on enteral versus parenteral nutrition across several GI settings, including inflammatory bowel disease (IBD), gastrointestinal oncology, critical care, and surgery.
It highlights that exclusive enteral nutrition can induce remission and support mucosal healing in IBD, while parenteral nutrition is appropriate for intestinal failure, severe complications, or when the gut cannot be used.
The report also notes interest in caloric/protein dosing, indirect calorimetry, supplemental parenteral nutrition practices, and impacts of nutrition support on the gut microbiome.
For patients: enteral nutrition (using the gut) is generally preferred when possible; intravenous (parenteral) nutrition is an important alternative for people with intestinal failure or severe complications after surgery or during critical illness.
Decisions should be individualized based on disease state, surgical status, and ability to tolerate enteral feeding. For clinicians: the review urges refinement of supplemental parenteral nutrition protocols and evidence-based, disease-specific approaches, and it points to growing data on how nutrition support affects the microbiome and clinical outcomes.
For researchers: priority areas include optimal dosing (calories/protein), utility of indirect calorimetry to tailor feeding, and the microbiome effects of different nutrition strategies.
Keep In Mind
This entry is based on a journal abstract (Current Opinion in Gastroenterology) summarizing recent literature; it is an expert review rather than a single clinical trial. Details and strength of evidence for specific recommendations will be in the full review text.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationCurrent opinion in gastroenterology
AuthorsRianna Deringer, Camila Schmeil Silva, Daniel Klein
InstitutionCleveland Clinic Florida, Weston, Florida, USA.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedSep 2, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Vitamin D in mucosal healing: therapeutic potential and current evidence in inflammatory bowel disease
Vitamin D may support intestinal barrier integrity and immune regulation—pathways central to mucosal healing and disease control in IBD. Understanding the evidence helps patients and clinicians consider vitamin D as a...
Lactiplantibacillus plantarum as a multifunctional probiotic for inflammatory bowel disease: Mechanisms, synbiotic strategies, and delivery systems.
This review highlights probiotic and synbiotic approaches centered on L. plantarum that aim to rebalance gut microbiota and support the intestinal barrier—areas of direct interest to people with IBD seeking adjunctive,...
Optimizing evidence based primary care framework for inflammatory bowel disease
People with IBD commonly have extraintestinal symptoms (mood disorders, fatigue, pain, nutritional problems) that affect quality of life and need proactive identification and management in primary care.